Oncogenomics and the development of new cancer therapies
- 27 May 2004
- journal article
- review article
- Published by Springer Nature in Nature
- Vol. 429 (6990) , 469-474
- https://doi.org/10.1038/nature02627
Abstract
Scientists have sequenced the human genome and identified most of its genes. Now it is time to use these genomic data, and the high-throughput technology developed to generate them, to tackle major health problems such as cancer. To accelerate our understanding of this disease and to produce targeted therapies, further basic mutational and functional genomic information is required. A systematic and coordinated approach, with the results freely available, should speed up progress. This will best be accomplished through an international academic and pharmaceutical oncogenomics initiative.Keywords
This publication has 86 references indexed in Scilit:
- Targeted therapies for the treatment of cancerThe American Journal of Surgery, 2003
- Beyond Herceptin and GleevecCurrent Opinion in Chemical Biology, 2003
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targetsBiochemical Society Transactions, 2003
- The genetics and genomics of cancerNature Genetics, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- STI571 (Gleevec™) as a paradigm for cancer therapyTrends in Molecular Medicine, 2002
- Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studiesAnti-Cancer Drugs, 2001
- The Sequence of the Human GenomeScience, 2001
- Initial sequencing and analysis of the human genomeNature, 2001